These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7747315)

  • 1. Extension of the volunteer challenge model to study South American cholera in a population of volunteers predominantly with blood group antigen O.
    Tacket CO; Losonsky G; Nataro JP; Wasserman SS; Cryz SJ; Edelman R; Levine MM
    Trans R Soc Trop Med Hyg; 1995; 89(1):75-7. PubMed ID: 7747315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers.
    García L; Jidy MD; García H; Rodríguez BL; Fernández R; Año G; Cedré B; Valmaseda T; Suzarte E; Ramírez M; Pino Y; Campos J; Menéndez J; Valera R; González D; González I; Pérez O; Serrano T; Lastre M; Miralles F; Del Campo J; Maestre JL; Pérez JL; Talavera A; Pérez A; Marrero K; Ledón T; Fando R
    Infect Immun; 2005 May; 73(5):3018-24. PubMed ID: 15845509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pathogenicity of nonenterotoxigenic Vibrio cholerae serogroup O1 biotype El Tor isolated from sewage water in Brazil.
    Levine MM; Black RE; Clements ML; Cisneros L; Saah A; Nalin DR; Gill DM; Craig JP; Young CR; Ristaino P
    J Infect Dis; 1982 Mar; 145(3):296-9. PubMed ID: 7061878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor.
    Chen WH; Cohen MB; Kirkpatrick BD; Brady RC; Galloway D; Gurwith M; Hall RH; Kessler RA; Lock M; Haney D; Lyon CE; Pasetti MF; Simon JK; Szabo F; Tennant S; Levine MM
    Clin Infect Dis; 2016 Jun; 62(11):1329-1335. PubMed ID: 27001804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.
    Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Fasano A; Michalski J; Kaper JB; Levine MM
    J Infect Dis; 1993 Dec; 168(6):1536-40. PubMed ID: 8245542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and immunologic characteristics of Vibrio cholerae O139 Bengal infection in North American volunteers.
    Morris JG; Losonsky GE; Johnson JA; Tacket CO; Nataro JP; Panigrahi P; Levin MM
    J Infect Dis; 1995 Apr; 171(4):903-8. PubMed ID: 7706818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and bacteriological studies of El Tor cholera after ingestion of known inocula in Thai volunteers.
    Suntharasamai P; Migasena S; Vongsthongsri U; Supanaranond W; Pitisuttitham P; Supeeranan L; Chantra A; Naksrisook S
    Vaccine; 1992; 10(8):502-5. PubMed ID: 1621412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Challenge clinical trial for evaluation of a vaccine candidate strain against cholera].
    Díaz Jidy M; Pérez Rodríguez A; Fernández Llanes R; Bravo Fariñas L; García Sánchez H; Valera Fernández R; García Imia L; Fando Calzada R; Menéndez Hernández J
    Rev Cubana Med Trop; 2010; 62(3):194-9. PubMed ID: 23437548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vibrio cholerae O1 can assume a chlorine-resistant rugose survival form that is virulent for humans.
    Morris JG; Sztein MB; Rice EW; Nataro JP; Losonsky GA; Panigrahi P; Tacket CO; Johnson JA
    J Infect Dis; 1996 Dec; 174(6):1364-8. PubMed ID: 8940236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a live, oral, attenuated vaccine against El Tor cholera.
    Taylor DN; Killeen KP; Hack DC; Kenner JR; Coster TS; Beattie DT; Ezzell J; Hyman T; Trofa A; Sjogren MH
    J Infect Dis; 1994 Dec; 170(6):1518-23. PubMed ID: 7995992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic susceptibility to cholera.
    Levine MM; Nalin DR; Rennels MB; Hornick RB; Sotman S; Van Blerk G; Hughes TP; O'Donnell S; Barua D
    Ann Hum Biol; 1979; 6(4):369-74. PubMed ID: 394667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of novel vaccine strains of Vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens.
    Lebens M; Karlsson SL; Källgård S; Blomquist M; Ekman A; Nygren E; Holmgren J
    Vaccine; 2011 Oct; 29(43):7505-13. PubMed ID: 21807059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.
    Cordero De Los Santos L; Feris-Iglesias J; Aloysia D'Cor N; Midde VJ; Patnaik BN; Thollot Y; Rasuli A; Desauziers E
    Hum Vaccin Immunother; 2018 Jun; 14(6):1403-1411. PubMed ID: 29470934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pasteur oral cholera vaccine: studies of reactogenicity, clinical acceptability and immunogenicity in human volunteers.
    Pitisuttitham P; Migasena S; Prayurahong B; Supanaranond W; Suntharasamai P; Supeeranan L; Chantra A; Naksrisook S
    Southeast Asian J Trop Med Public Health; 1993 Mar; 24(1):126-9. PubMed ID: 8362286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and strain differentiation of Vibrio cholerae by using polyclonal antibodies against outer membrane proteins.
    Martínez-Govea A; Ambrosio J; Gutiérrez-Cogco L; Flisser A
    Clin Diagn Lab Immunol; 2001 Jul; 8(4):768-71. PubMed ID: 11427424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABO blood group distributions in diarrhoea cases including cholera in Calcutta.
    Sircar BK; Dutta P; De SP; Sikdar SN; Deb BC; Pal SC; Mitra SS
    Ann Hum Biol; 1981; 8(3):289-91. PubMed ID: 7259106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a volunteer model of cholera with frozen bacteria as the challenge.
    Sack DA; Tacket CO; Cohen MB; Sack RB; Losonsky GA; Shimko J; Nataro JP; Edelman R; Levine MM; Giannella RA; Schiff G; Lang D
    Infect Immun; 1998 May; 66(5):1968-72. PubMed ID: 9573077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and Genetic Variation of Vibrio cholerae Isolated from Clinical and Environmental Sources in Thailand.
    Siriphap A; Leekitcharoenphon P; Kaas RS; Theethakaew C; Aarestrup FM; Sutheinkul O; Hendriksen RS
    PLoS One; 2017; 12(1):e0169324. PubMed ID: 28103259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of Vibrio cholerae O1 biotype El Tor serotype Inaba causing outbreaks of cholera in Orissa, India.
    Pal BB; Khuntia HK; Samal SK; Das SS; Chhotray GP
    Jpn J Infect Dis; 2006 Aug; 59(4):266-9. PubMed ID: 16936349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.